Abstract：
:Metastatic renal cell carcinoma (RCC) has a highly variable natural history and carries a dismal prognosis. Unlike many other tumors, RCC is generally unresponsive to cytotoxic, hormonal, and radiation adjuvant therapies after cytoreductive surgery. Different modalities of treatment have been tried and tested with modest success. Until recently, only immunotherapies such as interleukin-2 and interferon-alpha have been shown to provide a response, albeit in a minority of patients and often with severe treatment-associated toxicities. Other adjuvant therapies, such as active specific immunotherapy with Bacillus Calmette-Guerin and autologous renal tumor cell vaccines, have not provided alternative solutions. Recent approaches include heat-shock protein peptide complex 96 vaccine and cG250 monoclonal antibody therapy. Novel targeted therapies have been developed using our knowledge of the molecular genetics that belie RCC. This culminated in sorafenib and sunitinib, the first Food and Drug Administration-approved drugs for RCC in more than a decade in the United States. The future will see further trials being carried out in the development of targeted therapies with emphasis placed on patient selection. Staging systems will need to be updated to integrate molecular biomarkers, which could potentially act not just as diagnostic and prognostic predictors, but also as tools for appropriate patient selection for treatment. In the future, this could potentially lead us to our ultimate goal of personalized medicine.
journal_name
Clin Genitourin Cancerjournal_title
Clinical genitourinary cancerauthors
Yap TA,Eisen TGdoi
10.3816/CGC.2006.n.028subject
Has Abstractpub_date
2006-09-01 00:00:00pages
120-30issue
2eissn
1558-7673issn
1938-0682pii
S1558-7673(11)70174-4journal_volume
5pub_type
杂志文章,评审abstract：INTRODUCTION:Pelvic lymph node dissection (PLND) is not recommended for low-risk prostate cancer (PCa) patients. However, the rate of PLND in this population is unknown. METHODS:We queried the National Cancer Data Base for PCa patients who underwent robot-assisted radical prostatectomy from 2010 to 2013 and stratified...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章
doi：10.1016/j.clgc.2017.05.013
更新日期：2017-12-01 00:00:00
abstract：BACKGROUND:Local tumor ablation (LTA) and expectant management (EM) represent competing treatment modalities for patients with small renal masses (SRMs) who are unfit for surgery. We examined the potential social discrepancies in the access of LTA and EM. MATERIALS AND METHODS:A total of 1860 patients with cT1a kidney...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章
doi：10.1016/j.clgc.2015.10.011
更新日期：2016-04-01 00:00:00
abstract：BACKGROUND:Tumor location in bladder neck has reported to be a prognostic factor for non-muscle-invasive bladder cancer (NMIBC). We investigated the impact of bladder neck involvement (BNI) on recurrence in NMIBC using time-dependent covariate analysis. PATIENTS AND METHODS:We enrolled 585 Japanese patients who underw...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章
doi：10.1016/j.clgc.2019.10.005
更新日期：2020-04-01 00:00:00
abstract：PURPOSE:To determine the therapeutic value of lymph node dissection (LND) during cytoreductive nephrectomy (CN) and assess predictors of cancer-specific survival (CSS) in metastatic renal-cell carcinoma. PATIENTS AND METHODS:We identified 293 consecutive patients treated with CN at 4 academic institutions from March 2...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章,多中心研究
doi：10.1016/j.clgc.2017.10.004
更新日期：2018-04-01 00:00:00
abstract：BACKGROUND:The objective of this study was to investigate positive surgical margin (PSM) rates in patients with prostate cancer treated with radical prostatectomy (RP) and assess PSM impact on cancer-specific mortality (CSM). PATIENTS AND METHODS:Within the Surveillance, Epidemiology, and End Results (SEER) database (...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章
doi：10.1016/j.clgc.2018.09.024
更新日期：2019-02-01 00:00:00
abstract：BACKGROUND:Sunitinib malate, a targeted tyrosine kinase inhibitor, is standard of care for metastatic renal cell carcinoma (mRCC) and serves as the active comparator in several ongoing mRCC clinical trials. In this analysis we report benchmarks for clinical outcomes on the basis of International Metastatic Renal Cell C...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章,多中心研究,随机对照试验
doi：10.1016/j.clgc.2018.04.005
更新日期：2018-08-01 00:00:00
abstract：BACKGROUND:Limited information is available about the effect of bleomycin administration on the development of pulmonary toxicity in metastatic germ cell tumors (GCT). PATIENTS AND METHODS:A literature search was conducted to identify randomized trials of first-line chemotherapy for GCT. We conducted univariate and mu...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章,meta分析
doi：10.1016/j.clgc.2016.08.021
更新日期：2017-04-01 00:00:00
abstract：INTRODUCTION:Tumor stage and grade represent the best established predictors for the prognosis of upper tract urothelial carcinoma (UTUC). However, controversies still exist regarding the role of tumor necrosis, location, and multifocality in the prognosis of UTUC. We share our experience with 305 patients, reporting o...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章
doi：10.1016/j.clgc.2016.04.017
更新日期：2016-12-01 00:00:00
abstract：INTRODUCTION:In the first-line (1L) setting, pazopanib (PAZ) has been recommended by the National Comprehensive Cancer Network for the treatment of advanced renal cell carcinoma (aRCC). In 2018, immuno-oncology (IO) therapy became a commonly used 1L treatment option for aRCC. We report the real-world clinical outcomes ...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章,多中心研究
doi：10.1016/j.clgc.2019.10.010
更新日期：2020-02-01 00:00:00
abstract：PURPOSE:Similar to other molecularly targeted agents, temsirolimus, an inhibitor of mammalian target of rapamycin, has shown promising activity in advanced renal cell carcinoma. However, only a subset of patients appears to derive significant tumor responses. In an effort to identify potential predictors of response to...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章
doi：10.3816/CGC.2007.n.020
更新日期：2007-09-01 00:00:00
abstract：BACKGROUND:We characterized clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib who were long-term responders (LTRs), defined as patients having progression-free survival (PFS) > 18 months. PATIENTS AND METHODS:A retrospective analysis of data from 5714 patients with mRCC t...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章
doi：10.1016/j.clgc.2017.06.005
更新日期：2017-06-20 00:00:00
abstract：BACKGROUND:Level 1 evidence has demonstrated increased overall survival with cisplatin-based neoadjuvant chemotherapy for patients with muscle-invasive urothelial cancer. Usage remains low, however, in part because neoadjuvant chemotherapy will not be effective for every patient. To identify the patients most likely to...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章,多中心研究
doi：10.1016/j.clgc.2016.03.006
更新日期：2016-12-01 00:00:00
abstract：INTRODUCTION:We compared retrograde extraperitoneal open radical cystoprostatectomy (REORC) and robot-assisted radical cystoprostatectomy with intracorporeal diversion (iRARC) and have reported the early perioperative outcomes. PATIENTS AND METHODS:REORC and iRARC were each performed at a different tertiary high-volum...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章
doi：10.1016/j.clgc.2019.12.006
更新日期：2020-06-01 00:00:00
abstract：INTRODUCTION:Tumor regression grades (TRGs) quantify the pathologic response to neoadjuvant chemotherapy (NAC). The aim of the study was to investigate the prognostic value of TRGs in combination with the TNM classification in an independent cohort of patients with muscle-invasive bladder cancer (MIBC) treated with NAC...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章
doi：10.1016/j.clgc.2019.09.003
更新日期：2019-12-01 00:00:00
abstract：INTRODUCTION:Oxidative stress has been found to be associated with the progression of prostate cancer (PCa); however, human studies which identify differential roles of each oxidation pathway in PCa progression are lacking. We aimed to identify which oxidative stress markers, specifically lipid and global oxidation and...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章
doi：10.1016/j.clgc.2019.09.014
更新日期：2020-04-01 00:00:00
abstract：BACKGROUND:We compared the short-term oncologic and functional outcomes of salvage focal cryotherapy (SFC) with those of salvage total cryotherapy (STC) for radiotherapy (RT)-persistent/recurrent prostate cancer. MATERIALS AND METHODS:We queried the Cryo On-Line Database registry for men who had undergone SFC and STC ...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章
doi：10.1016/j.clgc.2019.11.009
更新日期：2020-06-01 00:00:00
abstract：:The purpose of this study was to assess the prognostic value of lactate dehydrogenase (LDH) in patients with metastatic prostate cancer (PC). A systematic review and meta-analysis was performed in March 2019 according to the Preferred Reporting Items for Systematic Review and Meta-analysis statement. Studies were deem...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章,meta分析
doi：10.1016/j.clgc.2019.07.009
更新日期：2019-12-01 00:00:00
abstract：BACKGROUND:The purpose of this study was to analyze trends of bladder cancer (BC) stages and incidence in Europe and the United States (US). MATERIALS AND METHODS:Tumor stages after radical cystectomy were assessed in a monocentric cohort from 2006 to 2016. BC incidence was assessed between 2004 and 2014 based on the ...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章
doi：10.1016/j.clgc.2019.10.008
更新日期：2020-06-01 00:00:00
abstract：INTRODUCTION/BACKGROUND:Targeted therapy has become the mainstay of treatment for mRCC. The efficacy of this therapy in the older population is poorly understood. PATIENTS AND METHODS:Data from patients with mRCC treated with first-line anti-VEGF therapy were collected through the International mRCC Database Consortiu...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章
doi：10.1016/j.clgc.2014.02.009
更新日期：2014-10-01 00:00:00
abstract：:The spontaneous intraperitoneal rupture of the urinary bladder is an extremely rare and life-threatening event. Often, there are difficulties in establishing the diagnosis. A patient with spontaneous perforation of the urinary bladder, 17 years after successful treatment of an adenocarcinoma of the prostate by pelvic ...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章
doi：10.3816/CGC.2007.n.006
更新日期：2007-03-01 00:00:00
abstract：BACKGROUND:In recent years, new-onset hypothyroidism was extensively reported in patients receiving sunitinib for malignancy. Effects of sunitinib on serum lipids are not described, however a hyperlipidemic state is commonly observed in hypothyroid patients. Here we report about the incidence and severity of hyperchole...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章
doi：10.1016/j.clgc.2014.08.009
更新日期：2015-04-01 00:00:00
abstract：BACKGROUND:Cisplatin-based neoadjuvant chemotherapy (NAC) before cystectomy improves survival in muscle-invasive urothelial bladder cancer (MIBC). The use of NAC before chemoradiation (CRT) has been limited, as these patients are often elderly, frail, and ineligible for cisplatin. However, the role of NAC in fit, cispl...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章
doi：10.1016/j.clgc.2018.09.021
更新日期：2019-02-01 00:00:00
abstract：UNLABELLED:To identify the effects of diagnostic ureteroscopy on intravesical recurrence, 104 patients who had undergone radical nephroureterectomy were analyzed. The number of patients with intravesical recurrence was 34 (32.6%) at a mean of 37 months. Multivariate Cox model analysis revealed that delayed nephroureter...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章
doi：10.1016/j.clgc.2015.07.008
更新日期：2016-02-01 00:00:00
abstract：BACKGROUND:We investigated the activity of lenalidomide, which has antiangiogenic, antineoplastic, and immunomodulatory properties, in chemotherapy-naive, castration-resistant prostate cancer (CRPC) patients. PATIENTS:Patients received 25 mg/d lenalidomide for 21 days in 28-day cycles, until disease progression or una...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章
doi：10.1016/j.clgc.2013.09.001
更新日期：2014-02-01 00:00:00
abstract：BACKGROUND:Among men with high-risk non-metastatic castrate-resistant prostate cancer (nmCRPC), we used network meta-analysis to compare non-steroidal anti-androgens (NSAAs) and stratified class-level meta-analysis to identify subgroups with particular benefit from NSAAs with androgen deprivation therapy versus androge...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章,评审
doi：10.1016/j.clgc.2020.02.005
更新日期：2020-10-01 00:00:00
abstract：BACKGROUND:The purpose of this study was to analyze contemporary trends for diagnosis and treatment of upper tract urothelial carcinoma (UTUC). PATIENTS AND METHODS:We identified all cases of UTUC in the National Cancer Database (NCDB) between 2004 and 2013. Data comprising tumor, patient, and facility factors were ex...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章
doi：10.1016/j.clgc.2018.01.015
更新日期：2018-08-01 00:00:00
abstract：BACKGROUND:There are no data on the patterns of care and outcome of elderly patients with mRCC treated with sunitinib. In a retrospective study, we assessed the routine use of first-line sunitinib in mRCC patients aged ≥ 70 years. PATIENTS AND METHODS:We reviewed the clinical files of 185 patients aged ≥ 70 years with...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章
doi：10.1016/j.clgc.2013.11.005
更新日期：2014-06-01 00:00:00
abstract：BACKGROUND:The aim of this study was to evaluate the outcome of patients with translocation renal cell carcinoma (RCC) treated with partial nephrectomy. PATIENTS AND METHODS:Our institutional review board-approved renal mass registry was queried for patients who underwent partial nephrectomy for a pathologically confi...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章
doi：10.1016/j.clgc.2014.12.008
更新日期：2015-06-01 00:00:00
abstract：BACKGROUND:Results from large randomized controlled trials combining docetaxel, abiraterone, celecoxib, or bisphosphonates with androgen deprivation therapy (ADT) in hormone-sensitive prostate cancer have emerged. However, in our knowledge, few data are available in patients older than 70 years. Therefore, we undertook...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章,meta分析
doi：10.1016/j.clgc.2019.05.001
更新日期：2019-08-01 00:00:00
abstract：INTRODUCTION:Pembrolizumab has been approved in the United States (US) for the first-line treatment of patients with advanced or metastatic urothelial carcinoma, who are ineligible for cisplatin-containing chemotherapy and with tumors expressing programmed death-ligand 1 (PD-L1) (Combined Positive Score ≥ 10), or ineli...
journal_title：Clinical genitourinary cancer
pub_type： 杂志文章
doi：10.1016/j.clgc.2020.07.006
更新日期：2020-07-16 00:00:00
